Larimar Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Larimar Therapeutics Inc 's ROA in the second quarter of 2026?
Larimar Therapeutics Inc recorded a cumulative net loss of $-173 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -89.66%.

However, within the Healthcare sector 731 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4236, from total ROA ranking in the first quarter of 2026 at 4953.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	54.88 %	23.13 %	-26.78 %	-13.93 %	-36.59 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-173	-166	-166	-132	-100
Return On Assets (TTM)	-89.66 %	-96.43 %	-102.04 %	-75.13 %	-54.46 %
LRMR's Total Ranking	# 4236	# 4953	# 4234	# 4112	# 4095
Total Assets (TTM) in million	230	209	146	186	148
Seq. Total Assets Change	10.2 %	42.97 %	-21.56 %	25.33 %	-12.39 %
Seq. Net Income Change	-	-	-	-	-

LRMR's 5 Years Annual ROA >> Back to LRMR Management Effectiveness >> Compare LRMR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 337
Sector	# 732
Overall	# 4209

Return On Assets Statistics
High	Average	Low
-26.64 %	-46.5 %	-101.43 %
(Jun 30 2023)		(Dec 31 2025)

News about Larimar Therapeutics Inc Return on Assets ROA

Larimar Therapeutics Receives FDA's Stamp of Approval for Revolutionary FA Treatment in START Program

BALA CYNWYD, Pa., May 30, 2024 - Leading biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) proudly announces its selection by the United States Food and Drug Administration (FDA) to participate in the pioneering Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. This significant milestone highlights Larimar s commitment to developing effective treatments for complex rare diseases. The FDA s endorsement of Larimar s breakthrough protein replacement therapy called nomlabofusp, designed to combat Friedreichs ataxia (FA), is expected to grant the company accelerated pathways towards pivotal study initiation and potential Biologics License Application (BLA) submission.
Nomlabofusp holds great promise for individuals grappling with the debilitating effects of FA, a rare neurodegenerative condition. By delivering the crucial frataxin to mitochondria, the therapy aims to directly address the root cause of FA. Larimar s selection into the START program showcases the company s demonstrated development program readiness, with particular emphasis on nomlabofusp s potential to meet the urgent medical needs of FA patients. The alignment of chemistry, manufacturing, and controls (CMC) development timelines with clinical development plans further solidifies the potential of nomlabofusp as a ground-breaking treatment option.

Larimar Therapeutics' Groundbreaking Study Shows Promise in Rare Friedreich's Ataxia Treatment

Larimar Therapeutics Promising Phase 2 Study Indicates Potential Breakthrough in Friedreich s Ataxia Treatment
BALA CYNWYD, Pa. - Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has announced positive top-line data from its Phase 2 dose exploration study of nomlabofusp (CTI-1601) in patients with Friedreich s ataxia (FA). This groundbreaking study offers hope for the thousands of individuals around the world affected by this rare disorder.
Friedreich s ataxia is a progressive neurodegenerative disease that primarily affects the nervous system and causes muscle weakness, loss of coordination, and impaired speech. Currently, there are no approved treatments for this debilitating condition.

Financial Statements
Larimar Therapeutics Inc 's Assets	$ 230 million	LRMR's Balance sheet
Larimar Therapeutics Inc 's Income	$ -33 million	Quarterly LRMR's Income Statement
LRMR's Income by Division		See LRMR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-26.78 %	116.84 %	-26.26 %	67.76 %	-26.48 %
Total Assets in million	146	199	92	125	74
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-166	-81	-37	-35	-51
Annual Return On Assets	-113.6 %	-40.47 %	-40.22 %	-28.38 %	-68.19 %

LRMR's 5 Years Annual ROA >> Back to LRMR Management Effectiveness >> Compare LRMR ROA to its Competitors

More Return On Assets Ratios
LRMR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LRMR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LRMR's Competitors
Subscribers only: Roa for Larimar Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LRMR's Customers

You may also want to know
LRMR's Roi	LRMR's Inventory Turnover Ratio	LRMR's Growth Rates	LRMR's Dividend Comparisons
	LRMR's Profitability Ratios	LRMR's Asset Turnover Ratio	LRMR's Dividend Growth
LRMR's Roe	LRMR's Valuation Ratios	LRMR's Financial Strength Ratios	LRMR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-31T03:09:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.